significantly associated with ED (Table 1 ). The average survival duration was significantly different between ED and non-ED groups (856.4 vs 933.8 days, P = 0.033). After adjusting for age, sex, body mass index, 6MWD, forced expiratory volume in the first second, Modified Medical Research Council scale, GOLD stage, exacerbation, serum highsensitivity C-reactive protein (hsCRP), and fibrinogen, the ED group had a significantly higher mortality than the non-ED group (P = 0.012; HR = 4.12; 95% CI: 1.37-12.39) (Figure 1 ).
Background and Aims: The Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have given joint recommendations on the identification, diagnosis and treatment of asthma-COPD overlap (ACO). These recommendations have been adapted for clinical use in many Asian countries including Taiwan. However, their application to clinical practice has never been systemically evaluated. In addition, there are no prevalence data of ACO in Taiwan. The aim of this study was to determine the proportion and clinical characteristics of ACO among a cohort of COPD patients.
Methods: This observational cross-sectional study was conducted in 5 medical centres in Taiwan. From October 2016 through April 2017, consecutive COPD patients visiting outpatient clinics were interviewed and enrolled into a prospective cohort. Clinical characteristics, pulmonary function data, and laboratory data were collected and analyzed.
Results: Three hundred and forty COPD patients were enrolled into this study. The mean age was 71.7 years and 320 (94.1%) patients were male. Based on investigators' diagnosis, 103 (30.3%) patients were ACO cases. The major difference of clinical characteristics between patients with or without ACO were age, age of COPD diagnosis, duration of ACO/-COPD treatment, family history of asthma, reversible airflow limitation, medication for patients, and comorbidity rate. Our data suggests that the physician diagnosis of ACO in Taiwan is mostly in concordance with GINA/GOLD guidelines. In addition, the treatment for ACO in Taiwan was also consistent with the GINA/GOLD recommendations. LABA/ICS was the major medication used to control ACO.
Conclusion:
In Taiwan, 30.3% COPD patients were diagnosed as having ACO. These COPD patients with asthma traits were younger, diagnosed with COPD earlier but treated with shorter duration. They also have higher percentages of comorbidities, family history of asthma, and reversible airflow limitation.
AP434
This abstract has been withdrawn. ) was developed by Korean pharmaceutical company (Ahn-Gook) and already proved to be superior in suppressing cough and sputum in patients with acute upper respiratory infection and chronic inflammatory bronchitis in previous phase III study. Thus, it can be assumed that AG NPP709 is effective in COPD patients with chronic bronchitis type, which is the main symptoms of cough and sputum.
Methods: Chronic bronchitis type COPD patients 1) with postbronchodilator (BDR) FEV1/FVC ratio < 70, 2) over the age of 40 years with smoking history more than 10 pack years, and 3) with symptoms of chronic bronchitis including cough and sputum for more than 3 months were enrolled. This prospective open-label single-arm clinical trial examined clinical efficacy through pulmonary function test (PFT), COPD assessment test (CAT) scores and systemic inflammation state assessed by CRP, fibrinogen, IL-6, TNF-α and IL-33. A total of 30 patients enrolled and received a follow-up test after taking AG NPP709 for 3 months.
Results: Total 30 patients were included, all patients were male, mean age was 71.9 AE .93. Of the total patients, 100% were ever smokers and mean smoking history was 46.8 AE 4.96 pack-years. The mean post-BDR FEV1/FVC ratio was 58.6 AE 1.4, FEV1 (%) was 75.9 AE 0.07. The mean total CAT score was 14.7 AE .14. Of this patients, 26 were followed up after 3 months. In paired t test, significant improvement (P < 0.05) was observed in total CAT score (P = 0.005), fibrinogen (P = 0.013). Three patients experienced mild gastrointestinal side effects such as nausea. No serious adverse event was developed Conclusion: AG NPP709 improved the symptoms, which is represented by the CAT score, in patients with chronic bronchitis type COPD, and improved systemic inflammation by significantly reducing fibrinogen levels. This study suggests that AG NPP709 can be used with efficacy and safety in chronic bronchitis type COPD patients.
